Study Participation Opportunities

Research helps us understand how to live well with diabetes and will eventually lead us to the cure.

Because of research, we have experienced monumental advancements in understanding what causes diabetes, how it affects the body, how to manage diabetes both physically and emotionally, and what contributes to the development of diabetes complications.

We encourage you to consider participation in one or more of the clinical research studies now available at UCSF and outlined below.

 

Type 1 diabetes opportunities:

  • Type 1 Diabetes Online Clinical Trials Screener: Find out if you or a loved one may be eligible for a Type 1 Diabetes Trial.

  • TrialNet Pathway to Prevention: This study is for the relatives of people with Type 1 Diabetes. Relatives of people with T1D have up to 15 times greater risk for developing T1D. First degree relatives ages 1 to 45 years old and second or third degree relatives between the ages of 1 and 20 can get screened for their risk of developing T1D. The results give an early warning sign for developing diabetes and provide access to prevention trials (For example Abatacept Study, see link below) and closer monitoring.

  • Abatacept Study: This is a prevention study for relatives of people with Type 1 Diabetes who have two or more positive auto-antibodies but don’t yet have diabetes (normal blood sugars). It is open to relatives ages 6 to 45 years old. Abatacept is an FDA approved medication for use in children as young as 6 for two types of juvenile arthritis (an autoimmune disease). Abatacept works by blocking T cells before they have a chance to attack insulin producing beta cells.

  • Hydroxychloroquine Study: This is a prevention study for relatives of people with Type 1 Diabetes who were previously enrolled in TrialNet Pathway to Prevention and were found to have two or more positive auto-antibodies. It is open to relatives ages 3 to 45 years old with normal blood sugar. Hydroxychloroquine is an FDA approved medication for treating malaria, lupus, and rheumatoid arthritis.

  • Tregs and IL-2 in Type 1 Diabetes (TILT): This is an intervention study for people with Type 1 Diabetes. Participants must be between ages 18 and 45 and within two years from diagnosis. This study will contribute to research testing if Tregs can stop the destruction of the insulin making cells in people diagnosed with type 1 diabetes.

  • Use of Sensors in Kids with type 1 Diabetes Study (US-KiDS): This is a one-time survey of parents and caregivers of children younger than 13 years of age who use continuous glucose monitoring (CGM).

  • Hybrid Closed Loop Insulin Delivery System Data Collection (HYCLO): This is a multi-site study of children and adults who are starting the Medtronic 670G hybrid closed loop system. Participants will complete a series of questionnaires about their experience with the 670G over the course of 1 year. If you are interested in learning more and want to be contacted about the study, please send a us a note at: [email protected].

 

Type 2 diabetes opportunities:

  • Study to Understand Gaining Access to blood glucose Records (SUGAR): In this randomized controlled trial, adults with type 2 diabetes who are 18 years of age and older will be given new blood glucose monitoring technologies to manage their diabetes. 

  • Sensors On Youth with Type 2 Diabetes (SOY-T2): This is a pilot study of young adults with type 2 diabetes looking at how they feel about using technology to manage blood sugar levels. This study will help learn if a sensor (or continuous glucose monitoring “CGM” system) and a smartphone app are useful tools. It is open to adolescents and young adults ages 13 to 21 years old who have had type 2 diabetes for at least 6 months. If you are interested in learning more and want to be contacted, please send us a note at: [email protected] or call (415) 514-8549.

---

For more information:

Email: [email protected]

Call: 844-T1D-UCSF (844-813-8273)